Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Merck KGaA. (3/2/20). "Press Release: Erbitux Approved for First-Line Use in China in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) [Not intended for UK-based media]". Darmstadt.

Region Region China
Organisations Organisation Merck KGaA
  Group Merck (DE) (Group)
  Organisation 2 National Medical Products Administration of China (NMPA, formerly CFDA)
  Group China (govt)
Products Product Erbitux®
  Product 2 fluorouracil (INN)
     


   
Record changed: 2020-03-11

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top